Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4369059 | 0.94 | MAPT (0.56) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL28150240 | 0.93 | MAPT (0.59) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL709035 | 0.93 | MAPT (0.59) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL7045028 | 0.93 | MAPT (0.59) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL599876 | 0.88 | KEAP1 (0.54) | TAAR1NAAAFFAR1LTA4HGRM2 | |
| Hydrochloric Acid SCHEMBL27428710 | 0.86 | KEAP1 (0.52) | TAAR1NAAAFFAR1LTA4HGRM2 | |
| SCHEMBL28130962 | 0.86 | TAAR1 (0.43) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL934548 | 0.85 | TAAR1 (0.53) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL20912447 | 0.83 | LTA4H (0.44) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 | |
| SCHEMBL21962294 | 0.83 | TAAR1 (0.47) | SMN1; SMN2HDAC3MAPK1ADRA1AHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4642784-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2025-11-05 | — | — | EP | disclosed |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2024145623-A1 | HETEROCYCLIC AND HETEROARYL COMPOUNDS AS INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| CN-118165002-A | Polycyclic compounds and methods of use thereof | 桑诺维恩药品公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3252057-B1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-3880659-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-11819833-B2 | Conducting polymer and carbon nitride based nanocomposite photocatalyst for degradation of aqueous organic pollutants | Najran University (SA) | 2023-11-21 | — | — | US | disclosed |
| US-20230330644-A1 | CONDUCTING POLYMER AND CARBON NITRIDE BASED NANOCOMPOSITE PHOTOCATALYST FOR DEGRADATION OF AQUEOUS ORGANIC POLLUTANTS | Najran University (SA) | 2023-10-19 | — | — | US | disclosed |
| US-11713397-B1 | Composition for forming corrosion resistant composite coating | KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) | 2023-08-01 | — | — | US | disclosed |
| US-5342912-A | Water-soluble; electroconductivity; electrodes | WUDL FRED (US) | 1994-08-30 | — | — | US | disclosed |
| WO-1994013295-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| US-5310781-A | Carboxy-substituted | THE REAGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-05-10 | — | — | US | disclosed |
| EP-0583421-A1 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1994-02-23 | — | — | EP | disclosed |
| EP-0262147-B1 | SELF-DOPED POLYMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-06-23 | — | — | EP | disclosed |
| WO-1992019617-A2 | SUBSTITUTED DIBENZOXAZEPINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE | G.D. SEARLE & CO. (US) | 1992-11-12 | — | — | WO | disclosed |
| EP-0512400-A1 | Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use | G.D. Searle & Co. (US) | 1992-11-11 | — | — | EP | disclosed |
| EP-0221806-B1 | SUBSTITUTED THIOPHENE-2-SULFANOMIDE AND ANTIGLAUCOMA COMPOSITIONS CONTAINING THEM | MERCK & CO. INC. (US) | 1990-01-10 | — | — | EP | disclosed |
| EP-0221806-A1 | Substituted thiophene-2-sulfanomide and antiglaucoma compositions containing them | MERCK & CO. INC. (US) | 1987-05-13 | — | — | EP | disclosed |
| US-4093622-A | Pyridine esters of cyclopropane-carboxylic acid | ZOECON CORPORATION (US) | 1978-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | SMN1; SMN2 506/4885HDAC3 416/4885MAPK1 3847/4885 |
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SLC6A3, SLC6A11, SLC6A13 | SMN1; SMN2 585/4885HDAC3 1641/4885MAPK1 2402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.